利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.03 秒)

    Tumor-associated peptides that bind to mhc-molecules
    3.
    发明申请
    Tumor-associated peptides that bind to mhc-molecules 有权
    与mhc分子结合的肿瘤相关肽

    公开(公告)号：US20100029573A1

    公开(公告)日：2010-02-04

    申请号：US11596802

    申请日：2005-05-24

    申请人： Toni Weinschenk ,  Claudia Lemmel ,  Hans-Georg Rammensee ,  Stefan Stevanovic

    发明人： Toni Weinschenk ,  Claudia Lemmel ,  Hans-Georg Rammensee ,  Stefan Stevanovic

    IPC分类号： A61K38/08 ,  C07K7/06 ,  A61P35/00 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10

    CPC分类号： C07K14/4748

    摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.

    摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及该肽用于制备药物和用于治疗肿瘤疾病的用途 和/或腺瘤性疾病。 此外，描述了包含至少一种肽的药物组合物。

    Method for identifying and quantifying of tumuor-associated
    6.
    发明授权
    Method for identifying and quantifying of tumuor-associated 有权
    确定和量化肿瘤相关的方法

    公开(公告)号：US07811828B2

    公开(公告)日：2010-10-12

    申请号：US10587876

    申请日：2005-01-28

    申请人： Claudia Lemmel ,  Hans-Georg Rammensee

    发明人： Claudia Lemmel ,  Hans-Georg Rammensee

    IPC分类号： G01N33/58 ,  G01N33/53 ,  G01N33/533

    CPC分类号： G01N33/6878 ,  C07K7/06 ,  G01N33/57484 ,  G01N33/6842 ,  G01N33/6848 ,  G01N2333/70539 ,  Y10T436/24

    摘要： Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.

    摘要翻译： 描述了用于鉴定和定量肿瘤相关肽的方法，其中提供了用于获得肽的第一至少两种不同来源（肿瘤和健康组织），并且彼此分开地来自不同来源的肽被化学修饰 通过使用相同元素的至少两种不同的稳定同位素以相同的方式。 随后，通过色谱法分离肽，并测定肽的氨基酸序列，其中通过使用稳定同位素来测定具有来自不同样品的相同序列的肽的相对量比例 化学改性。 此外，本发明涉及具有选自SEQ ID NO：1至36的氨基酸序列的肿瘤相关肽，所述氨基酸序列来自所述序列方案，其中所述肽具有与 人类主要组织相容性复合体（MHC）I类。 此外，本发明涉及肽用于制备药物和治疗肿瘤疾病和/或腺瘤性疾病的用途。 此外，描述了包含至少一种肽的药物组合物。

    Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
    8.
    发明授权
    Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes 失效
    来自人肿瘤抗原的免疫原性T辅助表位和使用所述表位的免疫治疗方法

    公开(公告)号：US08067529B2

    公开(公告)日：2011-11-29

    申请号：US11664627

    申请日：2005-09-09

    申请人： Hans-Georg Rammensee ,  Toni Weinschenk ,  Jörn Dengjel

    发明人： Hans-Georg Rammensee ,  Toni Weinschenk ,  Jörn Dengjel

    IPC分类号： C07H21/04 ,  C07K5/00 ,  C12N15/00

    CPC分类号： C07K14/4748

    摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

    摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症，特别是肾癌的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的338种来自人类肿瘤细胞系的HLA II类分子的新型肽序列。

    Method for Identifying and Quantifying of Tumour-Associated
    9.
    发明申请
    Method for Identifying and Quantifying of Tumour-Associated 有权
    肿瘤相关鉴定和定量方法

    公开(公告)号：US20080038285A1

    公开(公告)日：2008-02-14

    申请号：US10587876

    申请日：2005-01-28

    申请人： Claudia Lemmel ,  Hans-Georg Rammensee

    发明人： Claudia Lemmel ,  Hans-Georg Rammensee

    IPC分类号： A61K39/00 ,  A61K38/08 ,  A61P35/00 ,  C07H21/04 ,  C07K1/00 ,  C07K7/00 ,  C12N15/63 ,  G01N33/53 ,  G01N33/68

    CPC分类号： G01N33/6878 ,  C07K7/06 ,  G01N33/57484 ,  G01N33/6842 ,  G01N33/6848 ,  G01N2333/70539 ,  Y10T436/24

    摘要： Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.

    摘要翻译： 描述了用于鉴定和定量肿瘤相关肽的方法，其中提供了用于获得肽的第一至少两种不同来源（肿瘤和健康组织），并且彼此分开地来自不同来源的肽被化学修饰 通过使用相同元素的至少两种不同的稳定同位素以相同的方式。 随后，通过色谱法分离肽，并测定肽的氨基酸序列，其中通过使用稳定同位素来测定具有来自不同样品的相同序列的肽的相对量比例 化学改性。 此外，本发明涉及具有选自SEQ ID NO：1至36的氨基酸序列的肿瘤相关肽，所述氨基酸序列来自所述序列方案，其中所述肽具有与 人类主要组织相容性复合体（MHC）I类。 此外，本发明涉及肽用于制备药物和治疗肿瘤疾病和/或腺瘤性疾病的用途。 此外，描述了包含至少一种肽的药物组合物。